Article By:
KKD Healthcare Analytics
Wednesday, August 9, 2017 10:13 AM EDT
Cellectar Biosciences stock shot up as the company announced achieving overall survival of 22.5 months to date after a single dose infusion of 12.5mCi/m2 in patients with multiple myeloma.